IISc researchers design synthetic peptide capable of poisoning antibiotic-resistant bacteria

In animals infected with antibiotic-resistant bacteria, the peptide treatment caused an 18-fold reduction in bacterial load in the liver.

ByPTI

Published Jul 21, 2023 | 2:03 PM Updated Jul 21, 2023 | 2:04 PM

Peptide capable of poisoning antibiotic-resistant bacteria

Researchers at the Indian Institute of Science (IISc) have designed a short peptide capable of poisoning a key enzyme in disease-causing bacteria, including some of the most deadly and antibiotic-resistant species. 

Made from a short stretch of about 24 amino acids, the peptide mimics the action of a natural toxin which inhibits a class of enzymes called topoisomerases, according to Bengaluru-based IISc. 

These enzymes play a crucial role in unspooling and re-coiling bacterial DNA during replication and protein synthesis. They are an attractive target for antibiotics because the ones in bacteria are very different from those in humans, an IISc release said on Thursday, 20 July. 

Also Read: Kerala’s first BSL-3 modular facility gets approval from Centre

Fights antibiotic-resistant bacteria

Among the most widely used antibiotics are fluoroquinolones such as ciprofloxacin, which target these topoisomerases. 

However, overuse of these antibiotics around the world has led to the alarming rise of antibiotic-resistant bacteria, prompting scientists to pursue alternative strategies and molecules. 

Topoisomerases form a covalent adduct, an intermediate complex with the bacterial DNA, to coil or uncoil it. 

The peptide developed by the IISc team binds to this adduct and “traps” it in place, kicking off a cascade of events that lead to cell death, explains Raghavan Varadarajan, Professor at the Molecular Biophysics Unit (MBU), and one of the corresponding authors of the study published in “EMBO Reports”. 

Similar to CcdB

This is similar to how a natural toxin called “CcdB”, produced by certain other bacteria and plasmids, works. 

“The full-length CcdB protein is large. It is not feasible to use it as a drug in its entirety,” says first author Jayantika Bhowmick, former PhD student at MBU and currently a post-doctoral researcher at the University of Cambridge. 

Instead, the team snipped out a small stretch from the tail end of this protein and added a few more amino acids that would allow the new peptide to enter bacterial cells. 

The lab of Jayanta Chatterjee, a Professor at MBU carried out the peptide design. 

Also Read: Unravelling the aspartame mystery

New peptide tested 

The team then tested the new peptide’s effect on the growth of several disease-causing bacterial species, including E. coli, Salmonella Typhimurium, Staphylococcus aureus and a multidrug-resistant strain of Acinetobacter baumanii both in cell culture as well as animal models. This was done in collaboration with the lab of Dipshikha Chakravortty, a Professor at the Department of Microbiology and Cell Biology (MCB). 

They also compared the effect of their peptide against clinical doses of ciprofloxacin. Depending on the species, the peptide was found to either block or “poison” a specific type of topoisomerase, an enzyme called DNA gyrase in many of them explains Manish Nag, PhD student at MBU and another author. 

“It is (also) capable of disrupting most of the strains’ membranes,” he adds. 

18-fold reduction in bacterial load

In animal models, the peptide was found to drastically reduce infection. 

“In most of the cases, we saw that the decline in the bacterial count in major organs following peptide treatment was higher than in the ciprofloxacin-treated group. That was pretty encouraging to us,” says Bhowmick. 

For example, in animals infected with antibiotic-resistant Acinetobacter baumannii, the peptide treatment caused an 18-fold reduction in bacterial load in the liver, compared to only a 3-fold reduction by ciprofloxacin. 

The peptide was also found to be relatively safe and did not cause toxic reactions in the animals, the IISc release said. 

Since the peptide binds to a different site on the bacterial enzyme than ciprofloxacin, the researchers believe that it provides leads for the identification of drugs that can be used as a combination therapy with existing antibiotics.

Varadarajan adds that the study also reinforces the importance of targeting topoisomerases as a valid approach to finding new antibiotics.

(Disclaimer: The headline, subheads, and intro of this report along with the photos may have been reworked by South First. The rest of the content is from a syndicated feed, and has been edited for style.)